## Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 8-K

#### NEUROCRINE BIOSCIENCES INC

Form 8-K

November 27, 2001

\_\_\_\_\_\_

#### SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

\_\_\_\_\_

FORM 8-K

\_\_\_\_\_

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): November 27, 2001

# NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation) 0-28150 (Commission File Number) 33-0525145 (IRS Employer Identification Number)

10555 SCIENCE CENTER DRIVE, SAN DIEGO, CA (Address of principal executive offices)

92121 (Zip Code)

Registrant's telephone number, including area code: (858) 658-7600

N/A

(Former name or former address, if changed since last report.)

\_\_\_\_\_\_

This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a Delaware corporation (the "Company"), in connection with the matters described herein.

### ITEM 5. OTHER EVENTS

On November 27, 2001, the Company announced that it intends to file a preliminary prospectus supplement to its \$200 million universal shelf registration statement with the Securities and Exchange Commission relating to the proposed underwritten public offering of 3,250,000 shares of its common stock. A copy of the Company's press release announcing its intention to file a preliminary prospectus supplement, dated November 27, 2001, is attached hereto as Exhibit 99.1 and incorporated herein by reference.

# Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 8-K

## ITEM 7. EXHIBITS

(c) Exhibits. The following exhibits are filed herewith:

Exhibit

Number Description of Exhibit

99.1 Press Release, dated November 27, 2001.

#### SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 27, 2001 /s/ Paul W. Hawran

Paul W. Hawran

Executive Vice President and Chief Financial Officer

### EXHIBIT INDEX

EXHIBIT	
NUMBER	DESCRIPTION
99.1	Press Release, dated November 27, 2001.